Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 13Urogenital Neoplasms 2Prostatic Diseases 2Neoplasms by Site 2Neoplasms 2Genital Neoplasms, Male 2Breast Neoplasms 2Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Male Urogenital Diseases 1Genital Diseases, Male 1Castrate-resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1Advanced Prostate Cancer 1Adenocarcinoma 1

Interventions

dactolisib 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Castrate-resistant Prostate Cancer × Abiraterone Acetate × Clear all
NCT01717898 2018-03-27

A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

University of California, San Francisco

Phase 1/2 Terminated
6 enrolled 5 charts
Genitourinary

Castrate-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡